MX2022006149A - Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tim3. - Google Patents

Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tim3.

Info

Publication number
MX2022006149A
MX2022006149A MX2022006149A MX2022006149A MX2022006149A MX 2022006149 A MX2022006149 A MX 2022006149A MX 2022006149 A MX2022006149 A MX 2022006149A MX 2022006149 A MX2022006149 A MX 2022006149A MX 2022006149 A MX2022006149 A MX 2022006149A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
combination
cancer treatment
tim3
Prior art date
Application number
MX2022006149A
Other languages
English (en)
Spanish (es)
Inventor
Ye Liu
Beibei Jiang
Xiaomin Song
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of MX2022006149A publication Critical patent/MX2022006149A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022006149A 2019-11-21 2020-11-19 Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tim3. MX2022006149A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019120040 2019-11-21
PCT/CN2020/130003 WO2021098758A1 (en) 2019-11-21 2020-11-19 Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies

Publications (1)

Publication Number Publication Date
MX2022006149A true MX2022006149A (es) 2022-06-17

Family

ID=75980301

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006149A MX2022006149A (es) 2019-11-21 2020-11-19 Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tim3.

Country Status (12)

Country Link
US (1) US20230002501A1 (https=)
EP (1) EP4061845A4 (https=)
JP (1) JP2023503399A (https=)
KR (1) KR20220103105A (https=)
CN (2) CN118320076A (https=)
AU (1) AU2020387990A1 (https=)
BR (1) BR112022008184A2 (https=)
CA (1) CA3157319A1 (https=)
IL (1) IL293117A (https=)
MX (1) MX2022006149A (https=)
WO (1) WO2021098758A1 (https=)
ZA (1) ZA202204252B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020023746A2 (pt) 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
SG10201708048XA (en) * 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
HUE045065T2 (hu) * 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
DK3303396T5 (da) * 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
AU2016364891A1 (en) * 2015-12-03 2018-06-07 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
US11203637B2 (en) * 2016-08-26 2021-12-21 Beigene, Ltd. Anti-Tim-3 antibodies and use thereof
JP2021501801A (ja) * 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
CN111393529B (zh) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 与ox40l非竞争结合的抗ox40抗体
BR112020023746A2 (pt) * 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico

Also Published As

Publication number Publication date
CA3157319A1 (en) 2021-05-27
CN118320076A (zh) 2024-07-12
AU2020387990A1 (en) 2022-06-02
US20230002501A1 (en) 2023-01-05
CN114641500A (zh) 2022-06-17
JP2023503399A (ja) 2023-01-30
ZA202204252B (en) 2023-01-25
WO2021098758A1 (en) 2021-05-27
EP4061845A1 (en) 2022-09-28
EP4061845A4 (en) 2023-12-13
CN114641500B (zh) 2024-03-29
IL293117A (en) 2022-07-01
BR112022008184A2 (pt) 2022-07-12
KR20220103105A (ko) 2022-07-21

Similar Documents

Publication Publication Date Title
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2022006147A (es) Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
NZ777032A (en) Anti-nkg2a antibodies and uses thereof
ZA201803079B (en) Anti-dr5 antibodies and methods of use thereof
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EA201992402A1 (ru) Антитела против ilt4 и антигенсвязывающие фрагменты
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
EA202090791A1 (ru) Агонистические антитела против cd40
MX2022006148A (es) Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit.
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
ZA202008095B (en) Humanized antibodies against psma
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2021004226A (es) Terapia combinada contra el cáncer.
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2023008597A (es) Metodos de tratamiento del cancer usando anticuerpos anti-tigit en combinacion con anticuerpos anti-pd1.
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
MX2022006149A (es) Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tim3.